We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.

This treatment has been approved for sale to the public.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00040625
First Posted: July 4, 2002
Last Update Posted: March 15, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Eli Lilly and Company
July 2, 2002
July 4, 2002
March 15, 2007
 
ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.
This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.
Not Provided
Expanded Access
  • Drug: Pemetrexed
  • Drug: Cisplatin
Not Provided
 
Approved for marketing
Contact information is only displayed when the study is recruiting subjects
Brazil,   Egypt,   Saudi Arabia,   United States
 
 
NCT00040625
Not Provided
Eli Lilly and Company
Not Provided
Not Provided
Eli Lilly and Company
March 2007